US approval gives Pfizer the first and second-line settings.
ApexOnco Front Page
Recent articles
But, like Merck two weeks ago, GSK has failed to hit overall survival.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
The group reports responses with its CD123-targeting ADC, but cash is running short.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
